Wave Life Sciences initiates Phase 2a INLIGHT obesity trial
Wave Life Sciences Ltd. advanced its WVE-007 program into Phase 2a testing for obesity, following Phase 1 results that demonstrated a 14% reduction in visceral fat. The multidose study targets high-BMI patients to validate body composition improvements and cardiometabolic benefits. Future trials in 2H 2026 will explore combination therapies with incretins.
*this image is generated using AI for illustrative purposes only.
Wave Life Sciences Ltd. has initiated the Phase 2a multidose portion of the INLIGHT trial, a placebo-controlled study evaluating WVE-007 as monotherapy in individuals living with obesity. The trial targets patients with a high BMI of 35-50 kg/m2 and comorbidities, aiming to demonstrate body composition improvements and better cardiometabolic health biomarkers. This advancement follows positive Phase 1 data where the investigational GalNAc-siRNA showed clinically meaningful reductions in fat mass.
Phase 1 Results and Safety Profile
The ongoing Phase 1 single dose portion of the INLIGHT trial investigated WVE-007 in otherwise healthy individuals with an average BMI of 32 kg/m2. At six months of follow-up, a single 240 mg dose drove significant reductions in key physical metrics. The treatment was generally safe and well tolerated up to 600 mg, with data supporting the potential for once or twice-yearly dosing.
| Metric | Reduction at Six Months |
|---|---|
| Visceral fat | -14% (p<0.05) |
| Total fat | -5% |
| Waist circumference | -3% |
Phase 2a Objectives and Future Development
The Phase 2a portion includes individuals with higher BMI and body fat, with and without type 2 diabetes. This segment utilizes multiple assessments to inform further development of WVE-007 for obesity, as well as MASH, type 2 diabetes, and cardiovascular disease. The company is on track to initiate additional Phase 2 trials in 2H 2026 to evaluate WVE-007 in combination with incretins and as post-incretin maintenance.
How will the efficacy of WVE-007 compare to current incretin-based therapies in the target high BMI population?
What competitive advantages does the potential once or twice-yearly dosing schedule offer over existing daily or weekly obesity treatments?
What specific regulatory milestones will Wave Life Sciences need to achieve before initiating the planned combination trials with incretins in 2H 2026?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
